Amelioration of neurovascular deficits in diabetic rats by a novel aldose reductase inhibitor, GP-1447: Minor contribution of nitric oxide

Diabetes Research and Clinical Practice

Volumn 40, Issue 2, 1998, Pages 101-112

  Yoshida, Motoyuki ^a   Sugiyama, Yoshiko ^a   Akaike, Nobuhide ^a   Ashizawa, Naoki ^a   Aotsuka, Tomoji ^a   Ohbayashi, Shigeo ^a   Matsuura, Akihiro ^a  

^a Grelan Pharmaceutical Co   (Japan)

Author keywords

Aldose reductase inhibitor; Motor nerve conduction velocity; Nitric oxide; Sciatic nerve blood flow

Indexed keywords

3 [(4,5,7 TRIFLUOROBENZOTHIAZOL 2 YL)METHYL] 5 METHYLPHENYLACETIC ACID; ALDOSE REDUCTASE INHIBITOR; N(G) NITROARGININE; NITRIC OXIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD FLOW; BLOOD FLOW VELOCITY; CONTROLLED STUDY; DIABETES MELLITUS; HUMAN; MOTOR NERVE CONDUCTION; NEUROLOGICAL COMPLICATION; PATHOPHYSIOLOGY; RAT; SCIATIC NERVE;

ALDEHYDE REDUCTASE; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; ERYTHROCYTE DEFORMABILITY; MALE; MOTOR NEURONS; NEURAL CONDUCTION; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROARGININE; PHENYLACETATES; RATS; RATS, SPRAGUE-DAWLEY; SCIATIC NERVE; SORBITOL; THIAZOLES;

EID: 0031830913     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(98)00032-1     Document Type: Article

References (42)

1. Low P.A., Lagerlund T.D., McManis P.G. Nerve blood flow and oxygen delivery in normal, diabetic and ischemic neuropathy. Int. Rev. Neurobiol. 31:1989;355-438.
2. Cameron N.E., Cotter M.A. The relationship of vascular changes to metabolic factors in diabetes mellitus and their role in the development of peripheral nerve complications. Diabetes Metab. Rev. 10:1994;189-224.
3. Maxfield E.K., Cameron N.E., Cotter M.A., Dines K.C. Angiotensin II receptor blockade improves nerve function, modulates nerve blood flow and stimulates endoneurial angiogenesis in streptozotocin-diabetic rats. Diabetologia. 36:1993;1230-1237.
4. Ueno Y., Koike H., Nakamura Y., Ochi Y., Annoh S., Nishio S. Effects of beraprost sodium, a prostacyclin analogue, on diabetic neuropathy in streptozotocin-induced diabetic rats. Jpn. J. Pharmacol. 70:1996;177-182.
5. 1 analogue TFC 612 on diabetic neuropathy in streptozocin-induced diabetic rats. Comparison with aldose reductase inhibitor ONO 2235. Diabetes. 38:1989;832-838.
6. Hotta N., Kakuta H., Fukasawa H.et al. Effect of a potent new aldose reductase inhibitor, (5-(3-thienyl)tetrazol-1-yl)acetic acid (TAT), on diabetic neuropathy in rats. Diabetes Res. Clin. Pract. 27:1995;107-117.
7. Nakamura J., Koh N., Sakakibara F.et al. Polyol pathway, 2,3-diphosphoglycerate in erythrocytes and diabetic neuropathy in rats. Eur. J. Pharmacol. 294:1995;207-214.
8. Cameron N.E., Cotter M.A. Impaired contraction and relaxation in aorta from streptozotocin-diabetic rats: role of polyol pathway activity. Diabetologia. 35:1992;1011-1019.
9. + in normal, galactose-fed and diabetic rat lens. Biochim. Biophys. Acta. 841:1985;247-253.
10. Tesfamariam B., Brown M.L., Cohen R.A. Aldose reductase and myoinositol in endothelial cell dysfunction caused by elevated glucose. J. Pharmacol. Exp. Ther. 263:1992;153-157.
11. Otter D.J., Chess-Williams R. The effects of aldose reductase inhibition with ponalrestat on changes in vascular function in streptozotocin diabetic rats. Br. J. Pharmacol. 113:1994;576-580.
12. +)-ATPase in the slowing of nerve conduction in the streptozotocin diabetic rat. J. Clin. Invest. 94:1994;853-859.
13. Cameron N.E., Cotter M.A., Hohman T.C. Interactions between essential fatty acid, prostanoid, polyol pathway and nitric oxide mechanisms in the neurovascular deficit of diabetic rats. Diabetologia. 39:1996;172-182.
14. Tesfamariam B., Palacino J.J., Weisbrod R.M., Cohen R.A. Aldose reductase inhibition restores endothelial cell function in diabetic rabbit aorta. J. Cardiovasc. Pharmacol. 21:1993;205-211.
15. Ashizawa N., Yoshida M., Sugiyama Y.et al. Effects of a novel potent aldose reductase inhibitor, GP-1447, on aldose reductase activity in vitro and on diabetic neuropathy and cataract formation in rats. Jpn. J. Pharmacol. 73:1997;133-144.
16. Kashima S., Sohda A., Takeuchi H., Ohsawa T. Study of measuring the velocity of erythrocytes in tissue by the dynamic light scattering method. Jpn. J. Appl. Phys. 32:1993;2177-2182.
17. Kashima S., Nishikawa M., Kondo T., Ohsawa T. Model for measurement of tissue oxygenated blood volume by the dynamic light scattering method. Jpn. J. Appl. Phys. 31:1992;4097-4102.
18. Haberl R.L., Heizer M.L., Marmarou A., Ellis E.F. Laser-Doppler assessment of brain microcirculation: effect of systemic alterations. Am. J. Physiol. 256:1989;H1247-H1254.
19. Terashima H., Hama K., Yamamoto R.et al. Effect of a new aldose reductase inhibitor on various tissue in vitro. J. Pharmacol. Exp. Ther. 229:1984;226-230.
20. Reid H.L., Barnes A.J., Lock P.J., Dormandy J.A., Dormandy T.L. A simple method for measuring erythrocyte deformability. J. Clin. Pathol. 29:1976;855-858.
21. Schmalzer E.A., Skalak R., Usami S., Vayo M., Chien S. Influence of red cell deformability on filtration of blood cell suspensions. Biorheology. 20:1983;29-40.
22. Matsui T., Nakamura Y., Ishikawa H., Matsuura A., Kobayashi F. Pharmacological profiles of a novel aldose reductase inhibitor, SPR-210, and its effects on streptozotocin-induced diabetic rats. Jpn. J. Pharmacol. 64:1994;115-124.
23. Mizuno K., Kato N., Matsubara A., Nakano K., Kurono M. Effects of a new aldose reductase inhibitor, (2S,4S)-6-fluoro-2′,5′-dioxospiro[chroman-4,4′-imidazolidine]- 2-carboxamide (SNK-860), on the slowing of motor nerve conduction velocity and metabolic abnormalities in the peripheral nerve in acute streptozotocin-induced diabetic rats. Metabolism. 41:1992;1081-1086.
24. Cameron N.E., Cotter M.A., Dines K.C., Maxfield E.K., Carey F., Mirrlees D.J. Aldose reductase inhibition, nerve perfusion, oxygenation and function in streptozotocin-diabetic rats: dose-response considerations and independence from a myo-inositol mechanism. Diabetologia. 37:1994;651-663.
25. Miyoshi T., Goto I. Serial in vivo determinations of nerve conduction velocity in rat tails. Physiological and pathological changes. Electroencephalogr. Clin. Neurophysiol. 35:1973;125-131.
26. Calcutt N.A., Mizisin A.P., Kalichman M.W. Aldose reductase inhibition, Doppler flux and conduction in diabetic rat nerve. Eur. J. Pharmacol. 251:1994;27-33.
27. Cameron N.E., Cotter M.A. Rapid reversal by aminoguanidine of the neurovascular effects of diabetes in rats: modulation by nitric oxide synthase inhibition. Metabolism. 45:1996;1147-1152.
28. M. Dewhurst, E.J. Stevens, C. Karasu, D.R. Tomlinson, Effects of aminoguanidine on vasculature and nerves of streptozotocin-diabetic rats, in: N. Hotta, D.A. Greene, J.D. Ward, A.A.F. Sima, A.J.M. Boulton (Eds.), Diabetic Neuropathy: New Concepts and Insights, Elsevier, Amsterdam, 1995, pp. 109-114.
29. Nukada H., Powell H.C., Myers R.R. Perineurial window: demyelination in nonherniated endoneurium with reduced nerve blood flow. J. Neuropathol. Exp. Neurol. 51:1992;523-530.
30. Pieper G.M., Dondlinger L.A. Plasma and vascular tissue arginine are decreased in diabetes: Acute arginine supplementation restores endothelium-dependent relaxation by augmenting cGMP production. J. Pharmacol. Exp. Ther. 283:1997;684-691.
31. Williamson J.R., Chang K., Frangos M.et al. Perspectives in diabetes. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes. 42:1993;801-813.
32. 2+-binding activities due to oxygen free radicals. Basic Res. Cardiol. 85:1990;45-54.
33. Egan R.W., Paxton J., Kuehl F.A. Jr. Mechanism for irreversible self-deactivation of prostaglandin synthetase. J. Biol. Chem. 251:1976;7329-7335.
34. Wolff S.P., Crabbe M.J. Low apparent aldose reductase activity produced by monosaccharide autoxidation. Biochem. J. 226:1985;625-630.
35. Graier W.F., Simecek S., Wascher T.C., Holzmann S., Kukovetz W.R., Kostner G.M. The aldose-reductase inhibitor, zopolrestat, amplifies blood vessel relaxation by inhibition of cGMP-specific phosphodiesterase. Diabetologia. 38(Suppl. 1):1995;A262.
36. Bohlen H.G., Niggl B.A. Arteriolar anatomical and functional abnormalities in juvenile mice with genetic or streptozotocin-induced diabetes mellitus. Circ. Res. 45:1979;390-396.
37. Joyner W.L., Mayhan W.G., Johnson R.L., Phares C.K. Microvascular alterations develop in Syrian hamsters after the induction of diabetes mellitus by streptozotocin. Diabetes. 30:1981;93-100.
38. Ditzel J., Beaven D.W., Renold A.E. Early vascular changes in diabetes mellitus. Metabolism. 9:1960;400-407.
39. Powell H., Knox D., Lee S.et al. Alloxan diabetic neuropathy: electron microscopic studies. Neurology. 27:1977;60-66.
40. Lash J.M., Bohlen H.G. Structural and functional origins of suppressed acetylcholine vasodilation in diabetic rat intestinal arterioles. Circ. Res. 69:1991;1259-1268.
41. Robey C., Dasmahapatra A., Cohen M.P., Suarez S. Sorbinil partially prevents decreased erythrocyte deformability in experimental diabetes mellitus. Diabetes. 36:1987;1010-1013.
42. Kowluru R., Bitensky M.W., Kowluru A., Dembo M., Keaton P.A., Buican T. Reversible sodium pump defect and swelling in the diabetic rat erythrocyte: effects on filterability and implications for microangiopathy. Proc. Natl. Acad. Sci. USA. 86:1989;3327-3331.